ArticleFrontiers in oncology2025
Differential diagnosis of clear cell renal cell carcinoma with low signal intensity on T2WI from angiomyolipoma without visible fat on MR imaging.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Usefulness of the internal-to-external circle area ratio in contrast-enhanced CT to differentiate small (< 3 cm) fat-poor angiomyolipoma from renal cell carcinoma.BMC medical imaging · 2025Article
- Mitophagy-related gene TRIP13 predicts prognosis and immune response and promotes proliferation and migrationFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to determine the potential of magnetic resonance imaging (MRI) parameters in differentiating between angiomyolipoma without visible fat (AML.wovf) and clear cell renal cell carcinoma (ccRCC) with low signal intensity on T2-weighted imaging (T2WI). Materials and methods: This is a retrospective study involving 36 cases of ccRCC and 17 cases of AML.wovf from September 2016 to July 2023. All patients underwent histological examination on resected specimens and contrast-enhanced magnetic resonance imaging (CE-MRI). Clinical characteristics such as age, gender, and symptoms of hematuria and lumbago were recorded. A panel of MRI parameters were analyzed, including the tumor growth patterns, the wedge-shaped sign, pseudocapsule formation, the arterial-to-delayed enhancement ratio (ADER), and the apparent diffusion coefficient (ADC). The potential of these MRI parameters in distinguishing ccRCC from AML.wovf was finally determined and visualized in a nomogram. Results: There were no significant differences in age, gender, and clinical symptoms between the ccRCC and AML.wovf groups. The wedge-shaped sign was more prevalent in patients with AML.wovf ( Conclusion: A combination of MRI parameters, including the wedge-shaped sign, pseudocapsule formation, and ADC, can accurately differentiate between AML.wovf and ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.